Design Therapeutics (DSGN) Free Cash Flow (2020 - 2026)
Design Therapeutics recorded quarterly Free Cash Flow of -$16.4 million in Q1 2026, down 36.93% quarter-over-quarter from -$12.0 million in Q4 2025, and up 2.55% year-over-year from -$16.0 million in Q1 2025.
Design Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$16.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.55% year-over-year to -$16.4 million; the TTM figure through Mar 2026 stood at -$54.1 million (down 13.53% YoY), while the FY2025 annual figure was -$54.6 million, down 25.56% from the prior year.
- Free Cash Flow came in at -$16.4 million for Q1 2026 at Design Therapeutics, down from -$12.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$9.5 million in Q3 2024 to a low of -$17.5 million in Q1 2023.
- A 5-year average of -$13.3 million and a median of -$12.8 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow slumped 217.59% in 2022 and surged 34.67% in 2024, its largest moves.
- Design Therapeutics' Free Cash Flow stood at -$15.4 million in 2022, then rose by 16.61% to -$12.8 million in 2023, then climbed by 23.12% to -$9.9 million in 2024, then dropped by 21.7% to -$12.0 million in 2025, then plunged by 36.93% to -$16.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$16.4 million, -$12.0 million, and -$11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.43 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | -14.53 Mn |
| Jun 30, 2025 | -14.53 Mn |
| Mar 31, 2025 | -16.86 Mn |
| Mar 31, 2025 | -16.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -9.53 Mn |
| Sep 30, 2024 | -9.53 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Mar 31, 2024 | -12.63 Mn |
| Mar 31, 2024 | -12.63 Mn |
| Dec 31, 2023 | -12.83 Mn |
| Dec 31, 2023 | -12.83 Mn |
| Sep 30, 2023 | -14.59 Mn |
| Sep 30, 2023 | -14.59 Mn |
| Jun 30, 2023 | -13.89 Mn |
| Jun 30, 2023 | -13.89 Mn |
| Mar 31, 2023 | -17.51 Mn |
| Mar 31, 2023 | -17.51 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Sep 30, 2022 | -14.31 Mn |
| Sep 30, 2022 | -14.31 Mn |
| Jun 30, 2022 | -10.70 Mn |
| Jun 30, 2022 | -10.70 Mn |
| Mar 31, 2022 | -11.85 Mn |
| Mar 31, 2022 | -11.85 Mn |
| Dec 31, 2021 | -9.58 Mn |
| Dec 31, 2021 | -9.58 Mn |
| Sep 30, 2021 | -9.13 Mn |
| Sep 30, 2021 | -9.13 Mn |
| Jun 30, 2021 | -8.47 Mn |
| Jun 30, 2021 | -8.47 Mn |
| Mar 31, 2021 | -3.73 Mn |
| Mar 31, 2021 | -3.73 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Sep 30, 2020 | -1.86 Mn |
| Sep 30, 2020 | -1.86 Mn |
| Jun 30, 2020 | -1.31 Mn |
| Jun 30, 2020 | -1.31 Mn |
| Mar 31, 2020 | -2.66 Mn |
| Mar 31, 2020 | -2.66 Mn |